

KEY INFORMATION DOCUMENT



Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

AtlantiS China Healthcare Fund

PRODUCT

Product:	AtlantiS International Umbrella Fund AtlantiS China Healthcare Fund US Dollar Units
Manufacturer name:	AtlantiS Investment Management (Ireland) Limited
Product code:	IE00B1WL3F32
Website:	www.atlantis-investment.com
Competent Authority:	AtlantiS Investment Management (Ireland) Limited is authorised in Ireland and regulated by Central Bank of Ireland. This PRIIP is authorised in Ireland.
Domicile country:	Ireland

Document valid as at: 31 October 2023

You are about to purchase a product that is not simple and may be difficult to understand.

WHAT IS THIS PRODUCT?

Type:

UCITS

Term:

This product is not subject to any fixed term.

Objectives:

The fund aims to generate long-term capital appreciation.


The fund invests primarily in securities issued by companies listed in Hong Kong, the People's Republic of China, Singapore, the United States or the United Kingdom which are principally engaged in health related industries in China, including pharmaceuticals, bio-technology, medical devices, healthcare providers, hospitals, nursing homes and environmental protection. Such securities will include equity securities, equity-related securities, American Depositary Receipts, Global Depositary Receipts, debt securities (such as debentures, fixed or floating rate corporate or sovereign notes and bonds) of investment grade or below investment grade and money market instruments. (such as treasury bills, certificates of deposit, commercial paper and bankers acceptances). The fund will not invest in other open-ended collective investment schemes and will at all times invest more than 50% of its net asset value directly in equity securities. Subject to the equity securities quota, the fund may also invest in cash and in real estate investment trusts (REITs) which are listed on the Shanghai Stock Exchange, the Shenzhen Stock Exchange, the Singapore Stock Exchange or on the Hong Kong Stock Exchange provided that they do not affect the ability of the fund to meet its liquidity obligations. The fund may invest indirectly in the A-share market by purchasing equity linked securities which will constitute transferable securities which will be listed, traded or dealt on a recognised exchange or, unlisted securities. In the case of unlisted securities, such investment shall not exceed 10% of the fund's net asset value. The fund may invest in have direct access to A-shares listed on the Shanghai Stock Exchange via the Shanghai-Hong Kong Stock Connect scheme and/or the Shenzhen Stock Exchange via the Shenzhen- Hong Kong Stock Connect scheme. Exposure to A-shares through the Connect Schemes will not be more than 50% of the fund's net asset value.

The fund is considered to be actively managed in reference to the Hang Seng Healthcare Index (the "Benchmark") by virtue of the fact that it uses the Benchmark for performance comparison purposes. Certain of the fund's securities may be components of and may have similar weightings to the Benchmark. However the Benchmark is not used to define the portfolio composition of the fund or as a performance target and the Fund may be wholly invested in securities which are not constituents of the Benchmark.

Intended Retail Investor:

Individuals with investment experience who seek exposure to Chinese equities relating to the healthcare industry and aim to achieve long term capital appreciation.

WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?



The risk indicator assumes you keep the product for 3 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to cash in early. You may have to pay significant extra costs to cash in early.

Risk indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as class 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity of the fund to pay you.

Be aware of risks. Market price risk: The fund's assets consist principally of equities. The values of these instruments are determined by market forces and there is accordingly a risk that market prices can change in a way that is adverse to the fund's performance. A number of investment restrictions as set out in the prospectus are adopted to limit the exposure of the fund to negative changes in the price of any individual financial asset.

Currency risk: The fund is exposed to currency risk as its assets and liabilities may be denominated in a currency other than the functional currency of the fund, the USD. The fluctuations in the rate of exchange between the currency in which the asset or liability is denominated and the functional currency could result in an appreciation or depreciation in the fair value of that asset.

Interest rate risk: The majority of the funds' financial assets and financial liabilities are non-interest bearing. Therefore, the fund is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates;

Credit risk: The fund is exposed to limited credit risk as the Depositary holds all assets on behalf of the fund in a segregated account. The fund's financial assets are equity securities. All transactions are settled and paid for upon delivery of stock and by using approved brokers. The risk of default is considered minimal.

Liquidity risk: The fund invests the majority of its assets in securities and other instruments that are traded regularly and which are considered to be realisable under normal market conditions.

The above should not be considered to be an exhaustive list of the risks. Potential investors should be aware that an investment in a fund may be exposed to other risks of an exceptional nature from time to time.

Performance scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product / a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

Recommended minimum holding period: 3 years Investment 10 000 USD			
Survival Scenarios Minimum: There is no minimum guaranteed return. You could lose some or all of your investment.		If you exit after 1 year	If you exit after 3 years (recommended holding period)
Stress scenario	What might you get back after costs	3 040 USD	3 340 USD
	Average return each year	-69.57 %	- 30.64 %
Unfavourable scenario	What might you get back after costs	5 790 USD	5 410 USD
	Average return each year	-42.07 %	- 18.51 %
Moderate scenario	What might you get back after costs	9 720 USD	9 100 USD
	Average return each year	-2.76 %	- 3.1 %
Favourable scenario	What might you get back after costs	14 480 USD	12 990 USD
	Average return each year	44.78 %	9.11 %

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

Unfavourable: This type of scenario occurred for an investment between 09/2020 and 08/2023.

Moderate: This type of scenario occurred for an investment between 08/2014 and 07/2017.

Favourable: This type of scenario occurred for an investment between 01/2019 and 12/2021.

WHAT HAPPENS IF ATLANTIS INVESTMENT MANAGEMENT (IRELAND) LIMITED IS UNABLE TO PAY OUT?

The Fund does not include any protection from future market performance, so you could lose some or all of your investment. However, your investments are deposited with a third party custodian bank, which means that in case of default of the Fund Manager, you could be able to get back the current value of your investment.

WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods:

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- USD 10 000 is invested.

Investment 10 000 USD	If you exit after 1 year	If you exit after 3 years
Total costs	222 USD	620 USD
Annual Cost Impact*	2.22 %	2.15 %

*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be -0.95% before costs and -3.10% after costs.

Composition of Costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	We do not charge an entry fee for this product, but the person selling you the product may do so.	N/A
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	N/A
Ongoing costs		
Management fees and other administrative or operating costs	1.66% of the value of your investment per year. This is an estimate based on actual costs over the last year.	169 USD
Portfolio transaction costs	0.52% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	53 USD
Incidental costs taken under specific conditions		
Performance Fee	The fund charges performance fee - 20.00% of those gains achieved above a 5.00% annual increase in the net asset value of the fund subject to a high water mark.	0 USD

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MY MONEY OUT EARLY?

Recommended minimum holding period: 3 years

The above mentioned period has been defined in accordance to the product characteristics. It is determined on the basis of the fund's risk and reward profile. Your ideal holding period may be different from this minimum recommended holding period. We recommend that you discuss this with your advisor. If the holding period is shorter than the recommended minimum, this may have a negative impact on the fund's risk and reward profile. Any costs are shown under "Composition of costs" above.

HOW CAN I COMPLAIN?

Complaints about this product or the conduct of the Company should be sent to us using the following details.

Website: www.atlantis-investment.com
E-mail: investment@atlantis-investment.com
Telephone: +852 2110 6320

OTHER RELEVANT INFORMATION

- Alongside this document, we invite you to carefully consult the Prospectus on our website.
- The past performances of this product can be found here www.atlantis-investment.com.
- Please note that past performance is not indicative of future performance. It cannot provide a guarantee of returns that you will receive in the future.
- The previous scenarios document for this product can be found here www.atlantis-investment.com.